– USA, PA – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, announced the appointment of Kevin Lind to its Board of Directors, bringing more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit.
About Kevin R. Lind
Kevin Lind is a seasoned biotechnology executive with more than 20 years of leadership experience. He most recently served as President, CEO, and Board Member of Longboard Pharmaceuticals, where he led and transformed the Arena spinout into a leader in neurology and oversaw its $2.6 billion acquisition by H. Lundbeck A/S in 2024. Before his time at Longboard, Kevin Lind was EVP and CFO at Arena Pharmaceuticals, where he played a central role in its turnaround, including lucrative business development partnerships and execution of its spinout of Longboard in 2020. Over the course of his career, Kevin Lind has raised more than a billion dollars in capital to support innovative biotech companies. He began his career in investment banking at Lehman Brothers before joining TPG, where he focused on healthcare investing. In addition to his role with Avalo, Kevin Lind currently serves as Chairman of the Board of Apnimed, Inc.
Kevin Lind received a BS from Stanford University in Biological Sciences and an MBA from UCLA Anderson School of Management.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
For more: https://www.avalotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.